Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Comparing Infliximab and Adalimumab for Colitis
Clin Gastroenterol Hepatol; 2017 Aug; Singh, et al
Biologic-naïve patients with ulcerative colitis (UC) who are taking adalimumab are more likely to require hospitalization, when compared to those on infliximab, according to a study of more than 1,700 patients ages 15 to 75 years. Details of the investigation include the following:
- Patients on adalimumab had a hazard ratio for all-cause hospitalization of 1.84, when compared to those on infliximab.
- There was also a trend toward more UC-related hospitalizations in the adalimumab group.
- The likelihood of abdominal surgery was similar between the 2 groups, however.
Citation:
Singh S, Andersen NN, Andersson M, Loftus EV, Jess T. Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study. Clin Gastroenterol Hepatol. 2017;15:1218-1225.e7. doi:10.1016/j.cgh.2016.11.024.